NEW YORK, October 28, 2014 /PRNewswire/ --
Embase facilitates compliance with regulatory guidelines and competitive analysis for product development
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced Embase, the world's most comprehensive biomedical database that enables tracking and retrieval of drug-specific data, has been enhanced to support the retrieval of medical device information. The improvements support comprehensive post-market surveillance and device safety as well as the development of novel devices.
Embase, which is part of the Elsevier Life Science Solutions portfolio, will help users prepare for clinical evaluations and perform post-market surveillance for medical devices more effectively through newly added functionality.
Medical device manufacturers using Embase will be able to carry out systematic reviews and compile a range of technological reviews including health technology assessments, rapid advisories, comparative effectiveness reviews and clinical evaluations for a medical device. Users will be able to monitor the literature for adverse device effects, emerging public health threats, quality complaints and inaccurate or inappropriate statements on devices.
"Whether monitoring adverse device effects to comply with post-market surveillance or developing a novel device, searching and identifying medical device-specific information in the literature is critical for manufacturers," said Daan de Jong, Director of Product Development, Elsevier. "As the body of scientific literature continues to expand, carrying out this comprehensive monitoring is becoming a significant challenge. Embase boasts wide literature coverage and now has dedicated functionality for medical devices, so manufacturers can feel confident they have tools to be fully compliant."
Data from Embase can be delivered in a flexible manner, allowing for better integration with customers' existing workflows and tools for post market surveillance. Customers can also incorporate data into their alerting systems to drive a more effective monitoring process with comprehensive information on regulatory changes and adverse events. Additionally, Embase works together with QUOSA, Elsevier's scientific literature management solution supporting retrieval, storage, tagging and annotation of scientific literature to deliver an end-to-end workflow for the screening, organizing, archiving and sharing of medical device literature.
Embase customers were automatically upgraded to a new version on July 31, 2014. Others interested in learning more about Embase and Elsevier's pharmacovigilance solutions can request additional information at: http://www.elsevier.com/online-tools/embase/contact-sales.
About Elsevier Life Science Solutions
Elsevier Life Science Solutions is a portfolio of domain-specific decision support tools, including ScienceDirect, Pathway Studio®, Reaxys®, Reaxys® Medicinal Chemistry, Embase™ and PharmaPendium®. Designed by scientists for scientists, the tools work together to help you create innovative drug therapies and reduce the time and cost of bringing them to market.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Director, Strategic Communications